Human medicines European public assessment report (EPAR): Docetaxel Kabi, docetaxel, Date of authorisation: 22/05/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Synjardy, empagliflozin,metformin, Date of authorisation: 27/05/2015, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Thiotepa Riemser, thiotepa, Date of authorisation: 26/03/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Neuraceq, florbetaben (18F), Date of authorisation: 20/02/2014, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Cholib, fenofibrate,simvastatin, Date of authorisation: 26/08/2013, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Firazyr, icatibant, Date of authorisation: 11/07/2008, Revision: 29, Status: Authorised